Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | BND-22 |
Trade Name | |
Synonyms | BND22|BND 22|SAR444881 |
Drug Descriptions |
BND-22 is an anti-ILT2 monoclonal antibody that blocks ILT2 from interacting with HLA-G, potentially leading to immunosuppressive effects and subsequent anti-tumor activity, including increased macrophage activity and inhibition of tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 3266). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C179566 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BND-22 | BND-22 | 0 | 1 |
BND-22 + Cemiplimab | BND-22 Cemiplimab | 0 | 1 |
BND-22 + Cetuximab | BND-22 Cetuximab | 0 | 0 |
BND-22 + Pembrolizumab | BND-22 Pembrolizumab | 0 | 0 |